Gennao Bio to Participate in Chardan’s 5th Annual Genetic Medicines Conference

HOPEWELL, N.J.--(BUSINESS WIRE)--Gennao Bio, a privately held genetic medicines company developing first-in-class, targeted nucleic acid therapeutics, today announced that management will participate in Chardan’s 5^th Annual Genetic Medicines Conference, being held virtually from October 4-5, 2021. The details are as follows:

Event: Chardan’s 5^th Annual Genetic Medicines Conference
Panel: RNA: RNA-based Targeted Delivery Approaches
Location: Virtual
Date: Tuesday, October 5, 2021
Time: 3:00 PM ET

Members of the Gennao Bio management team will also host investor meetings during the conference. A webcast of the panel discussion will be available on the company’s website at www.gennao.com for 30 days following the event.

About Gennao Bio

Gennao Bio is a privately held genetic medicines company developing first-in-class targeted nucleic acid therapeutics utilizing a proprietary gene monoclonal antibody (GMAB) platform technology. GMAB is an adaptive technology that uses a novel, cell-penetrating antibody to non-covalently bind to and deliver therapeutic levels of a wide variety of nucleic acid payloads to select cells. This non-viral delivery platform is differentiated from traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and employs well-established manufacturing processes. Gennao Bio is developing this delivery system with an initial focus on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases.